Associated Papers
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Lucas CG et al.
Neuro-oncology, 2025
Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.
Wells L et al.
Current Treatment Options in Oncology, 2023
Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study.
Hirakawa T et al.
Respiratory Investigation, 2023
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC et al.
Current Oncology (toronto, Ont.), 2022
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
Zeng Y et al.
Bmc Cancer, 2022
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
Kong LR et al.
Nature Communications, 2020
Systematic evaluation of PAXgene® tissue fixation for the histopathological and molecular study of lung cancer.
Southwood M et al.
The Journal of Pathology. Clinical Research, 2020
Precision medicine and actionable alterations in lung cancer: A single institution experience.
Mambetsariev I et al.
Plos One, 2020
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M et al.
Journal of Hematology & Oncology, 2017
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
Unni AM et al.
Elife, 2015
The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
Na II et al.
Lung Cancer (amsterdam, Netherlands), 2007
Bronchoalveolar Lavage as Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer.
Lin X et al.
Technology in Cancer Research & Treatment, 0